RxSense has partnered with Scipher Medicine, a precision immunology company matching patients with their most effective therapy, to deliver better patient treatment for rheumatoid arthritis (RA). Now, RxSense enterprise clients can conveniently access Scipher’s PrismRA® molecular signature test, which helps identify the optimal targeted therapy for patients with RA.
“Often RA patients waste valuable time trying multiple therapies before the most effective medication is prescribed,” said Ramzi Yacoub, Chief Pharmacy Officer at RxSense. “Through our new partnership with Scipher, we’re providing pharmacy benefit managers access to another powerful tool that brings transparency and efficiency in determining the best course of action for treatment.”
Specialty drug spend is one of the largest contributors to increasing healthcare costs. An estimated $552 billion is wasted each year when patients are prescribed drugs to which they don’t respond, placing a significant burden on the healthcare system at large. Most RA patients are prescribed the world’s largest selling drug class—tumor necrosis factor inhibitors (TNFi) therapies—yet the majority don’t respond to treatment.
PrismRA accurately predicts which patients will have an inadequate response, so they can avoid TNFi therapy and start effective alternative targeted therapies instead, helping them reach their treatment goals earlier while also eliminating unnecessary dose escalations and cycling through multiple ineffective drugs.
“We are proud to be partnering with an innovations-driven company like RxSense to make PrismRA available to their clients,” said Alif Saleh, Scipher Medicine CEO. “In the absence of precision medicine for RA, our breakthrough technology empowers pharmacy benefit managers to solve some of healthcare’s biggest drug problems—excess waste and poor patient outcomes.”